Cost Effectiveness Analysis for the Use of Extended Release Quetiapine as Adjunctive Therapy in Mexican Adult Patients with Major Depressive Disorder Non-Responders to Antidepressant Treatment

Cost Effectiveness ◽

Depressive Disorder ◽

Adjunctive Therapy ◽

Extended Release ◽

Antidepressant Treatment ◽

Adult Patients ◽

Major Depressive ◽

PMH49 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

Value in Health ◽

10.1016/s1098-3015(10)72544-4 ◽

2010 ◽

Vol 13 (3) ◽

pp. A113

Author(s):

C Taneja ◽

G Oster ◽

Y Jing ◽

RA Baker ◽

RA Forbes ◽

...

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Adjunctive Therapy ◽

Atypical Antipsychotics ◽

Adult Patients ◽

Major Depressive

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria

Current Medical Research and Opinion ◽

10.1185/030079904125003737 ◽

2004 ◽

Vol 20 (6) ◽

pp. 869-878 ◽

Cited By ~ 24

Author(s):

Michiel E. H. Hemels ◽

Siegfried Kasper ◽

Evelyn Walter ◽

Thomas R. Einarson

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Line Treatment ◽

First Line ◽

Major Depressive ◽

Effectiveness Analysis ◽

First Line Treatment

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

Current Medical Research and Opinion ◽

10.1185/030079905x41462 ◽

2005 ◽

Vol 21 (4) ◽

pp. 631-641 ◽

Cited By ~ 22

Author(s):

Alan G. Wade ◽

Idris Toumi ◽

Michiel E. H. Hemels

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Line Treatment ◽

First Line ◽

Major Depressive ◽

Effectiveness Analysis ◽

The Uk ◽

First Line Treatment

PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Value in Health ◽

10.1016/j.jval.2019.09.1501 ◽

2019 ◽

Vol 22 ◽

pp. S685

Author(s):

G. Wang ◽

K. Zhao ◽

C. Reynaud-Mougin ◽

H. Loft ◽

H. Ren ◽

...

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

Asian Patients ◽

PMH28 A COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM AND SERTRALINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Value in Health ◽

10.1016/s1098-3015(10)63063-x ◽

2005 ◽

Vol 8 (3) ◽

pp. 393 ◽

Cited By ~ 1

Author(s):

EP Armstrong ◽

GH Skrepnek ◽

DC Malone ◽

H Erder

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

PMH46 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY

Value in Health ◽

10.1016/s1098-3015(10)67792-3 ◽

2005 ◽

Vol 8 (6) ◽

pp. A210

Author(s):

W Kulp ◽

M Hemels ◽

W Greiner ◽

J Schulenburg Graf von der

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach

Value in Health Regional Issues ◽

10.1016/j.vhri.2013.06.004 ◽

2013 ◽

Vol 2 (2) ◽

pp. 171-180 ◽

Cited By ~ 3

Author(s):

Mete Saylan ◽

M.J. Treur ◽

R. Postema ◽

N. Dilbaz ◽

H. Savas ◽

...

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1723072 ◽

2020 ◽

Vol 36 (5) ◽

pp. 875-882 ◽

Cited By ~ 1

Author(s):

Gang Wang ◽

Kun Zhao ◽

Caroline Reynaud-Mougin ◽

Henrik Loft ◽

Hongye Ren ◽

...

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

Asian Patients ◽

Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

International Journal of Psychiatry in Clinical Practice ◽

10.1080/13651500802450506 ◽

2009 ◽

Vol 13 (1) ◽

pp. 59-69 ◽

Cited By ~ 2

Author(s):

Feng Xie ◽

Nicolas Despiegel ◽

Natalya Danchenko ◽

Karina Hansen

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽

PMH26 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY

Value in Health ◽

10.1016/s1098-3015(10)63061-6 ◽

2005 ◽

Vol 8 (3) ◽

pp. 392 ◽

Cited By ~ 2

Author(s):

ME Hemels ◽

O Karamustafaloglu ◽

E Ozmen ◽

S Dilsad ◽

S Mene

Keyword(s):

Cost Effectiveness ◽

Depressive Disorder ◽

Major Depressive ◽